Trinity Biotech Plc Sponsored ADR Class A Stock

$1.13

35.59% yesterday

Nasdaq, Aug 12, 10:15 pm CET

ISIN

US8964383066

Symbol

TRIB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Trinity Biotech Plc Sponsored ADR Class A Stock price

$1.13

-9.77 89.63% 5Y

Nasdaq, Closing price Tue, Aug 12 2025

+0.30 35.59%

ISIN

US8964383066

Symbol

TRIB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$15.1m

Enterprise Value

$110.7m

Net debt

$95.6m

Cash

$5.2m

Shares outstanding

30.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.2 | 0.2

EV/Sales

1.8 | 1.6

EV/FCF

negative

P/B

negative

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | 0.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$61.6m | $69.9m

EBITDA

$-16.0m | -

EBIT

$-17.9m | $-6.1m

Net Income

$-31.8m | $-28.1m

Free Cash Flow

$-14.3m

Growth (TTM | estimate)

Revenue

8.3% | 13.5%

EBITDA

-13.1% | -

EBIT

-12.2% | 61.9%

Net Income

-32.3% | 11.7%

Free Cash Flow

0.0%

Financial Health

Equity Ratio

-34.1%

Return on Equity

90.4%

ROCE

-25.1%

ROIC

-26.5%

Debt/Equity

-2.9

EPS

$-0.1

FCF per Share

$-0.5

Short interest

3.7%

Employees

380

Rev per Employee

$160.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Trinity Biotech Plc Sponsored ADR Class A Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Trinity Biotech Plc Sponsored ADR Class A forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Trinity Biotech Plc Sponsored ADR Class A forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Trinity Biotech Plc Sponsored ADR Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	62 62	8% 8% 100%
- Direct Costs	40 40	7% 7% 65%
Gross Profit	21 21	10% 10% 35%
- Selling and Administrative Expenses	33 33	6% 6% 54%
- Research and Development Expense	4.54 4.54	4% 4% 7%
EBITDA	-16 -16	13% 13% -26%
- Depreciation and Amortization	1.87 1.87	5% 5% 3%
EBIT (Operating Income) EBIT	-18 -18	12% 12% -29%
Net Profit	-32 -32	32% 32% -52%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Trinity Biotech Plc Sponsored ADR Class A Stock News

Neutral

GlobeNewsWire

●

about 18 hours ago

Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company's next-generation CGM+ biosensor platform Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company's next-generation CGM+ biosensor platform

Neutral

GlobeNewsWire

●

6 days ago

Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service

FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, incl...

Neutral

GlobeNewsWire

●

20 days ago

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market

WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market. Now in the later ...

More Trinity Biotech Plc Sponsored ADR Class A News

Company Profile

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

Head office	Ireland
CEO	John Gillard
Employees	380
Founded	1992
Website	www.trinitybiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now